Evidence map›Paper›PMID 26821711›Full record

ArticleJournal of neuro-oncology2016

Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.

Wenyin Shi, Joshua D Palmer, Maria Werner-Wasik, David W Andrews, James J Evans, Jon Glass, Lyndon Kim, Voichita Bar-Ad, Kevin Judy, Christopher Farrell and 4 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. A Perspective of Epigenetic Regulation in Radiotherapy.Frontiers in cell and developmental biology · 2021
    Review
  18. Review
  19. Article
  20. Epigenetic Targeting of Glioblastoma.Frontiers in oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenyin ShiDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA. Wenyin.shi@jefferson.edu.
Joshua D PalmerDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
Maria Werner-WasikDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
David W AndrewsDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
James J EvansDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Jon GlassDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Lyndon KimDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Voichita Bar-AdDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
Kevin JudyDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Christopher FarrellDepartment of Neurosurgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Nicole SimoneDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
Haisong LiuDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
Adam P DickerDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.
Yaacov R LawrenceDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, 19107, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Panobinostat is an oral HDAC inhibitor with radiosensitizing activity. We investigated the safety, tolerability and preliminary efficacy of panobinostat combined with fractionated stereotactic re-irradiation therapy (FSRT) for recurrent high grade gliomas. Patients with recurrent high grade gliomas were enrolled in a 3 + 3 dose escalation study to determine dose limiting toxicities (DLTs), maximum tolerated dose (MTD), safety, tolerability, and preliminary efficacy. FSRT was prescribed to 30-35 Gy delivered in 10 fractions. Panobinostat was administrated concurrently with radiotherapy. Of 12 evaluable patients, 8 had recurrent GBM, and 4 had recurrent anaplastic astrocytoma. There were three grade 3 or higher toxicities in each the 10 and 30 mg cohorts. In the 30 mg cohort, there was one DLT; grade 4 neutropenia. One patient developed late grade 3 radionecrosis. The median follow up was 18.8 months. The PFS6 was 67, 33, and 83 % for 10, 20, and 30 mg cohorts, respectively. The median OS was 7.8, 6.1 and 16.1 months for the 10, 20 and 30 mg cohorts, respectively. Panobinostat administrated with FSRT is well tolerated at 30 mg. A phase II trial is warranted to assess the efficacy of panobinostat plus FSRT for recurrent glioma.

Indexed as

RadiosurgeryRe-IrradiationAdultAgedAntineoplastic AgentsBrain NeoplasmsCombined Modality TherapyDose Fractionation, RadiationFemaleFollow-Up StudiesGliomaHumansHydroxamic AcidsIndolesMaleMaximum Tolerated DoseAntineoplastic AgentsHydroxamic AcidsIndolesPanobinostatHDAC inhibitorPanobinostatPhase I trialRadiotherapyRecurrent high grade glioma

Identifiers

PMID26821711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.